News

The approval of the third-generation trifocal intraocular lens broadens the range of advanced lens options available for patients in the US.

From lasers to lenses, the 1970s redefined vision care through breakthroughs in surgery, imaging, and therapeutics.

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and convenience of anti-VEGF therapy.

The epithelium-on cross-linking modality is designed to enable simultaneous, bilateral keratoconus treatment, according to Epion Therapeutics.

The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life.

Patients with proliferative diabetic retinopathy, central retinal vein occlusion and branch retinal vein occlusion experienced fluctuating retinal perfusion, investigators reported

The FDA describes the RDEA pilot program as a program to support novel endpoint efficacy development for drugs that treat rare diseases.

Emerging pharmacological and optical strategies are shaping a new era.

Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.

The Polaris platform is the world’s first AI-supported and robotics-enabled surgical system developed specifically for ophthalmology, according to the company.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

EYDENZELT is Celltrion's first FDA-approved biologic product in ophthalmology.

Singh highlights how understanding the “why” behind diagnostics and procedures boosts technician confidence, fosters pride, and strengthens their role in patient care.

A recent study uncovers a novel biomarker for retinal vascular diseases, highlighting the significance of intermittent capillary perfusion in monitoring treatment efficacy.

Biomarkers and fine-tuned staging are key to progress in improving retinal care, according to Fanka Gilevska, MD, PhD.

Dr Chhablani said "having multiple approaches to the same problem" is key for reaching the maximum number of patients with age-related macular degeneration

Ultra-high-resolution OCT advances retinal imaging, enabling detailed visualization of disease progression and potential therapeutic effects in eye conditions.

The Phase 1/2 ArMaDa trial is evaluating OCU410 (Ocugen), a gene therapy candidate for patients with dry age-related macular degeneration.

The video-driven platform equips ophthalmic practices with tools to standardize education, improve workflow, and foster technician engagement.

Sura-vec is intended to be a potential 1-time treatment consisting of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF).

Maximizing treatment based on GA location, lesion progression, and morphologic retinal changes.

The agenda includes subspecialty days, evening events and partner programmes from practice management organisations

A young surgeon reflects on training, technology, and the human side of adopting new excimer laser platforms.

Join the American Academy of Ophthalmology's annual meeting for cutting-edge insights, networking, and engaging events from October 17-20 in Orlando.

The company can now initiate the Opti-GAIN (Optimized Geographic Atrophy INterventional) phase 1/2 clinical trial.

Real-world insights emphasize identifying underlying causes to tailor treatment.